DEEPBLOCK: Deep Neuromuscular Block for Laparoscopic Surgery
Study Details
Study Description
Brief Summary
Trial summary: deep neuromuscular block is proposed as a technique to improve operative conditions for laparoscopy. Early clinical data would suggest that there may also be patient benefits beyond the operative period related to lower intra-abdominal pressure, and improved surgical exposure. In order to safely conduct deep neuromuscular blockade, it is essential to use Sugammadex to reverse the neuromuscular block. Conventional practice is to provide moderate neuromuscular block and reverse with neostigmine. It is not possible to safely reverse deep neuromuscular block using neostogmine, as the majority of block must have worn off for neostigmine to be effective. in order to identify whether deep neuromuscular block improves quality of recovery after surgery, the investigators will conduct a randomised trial of deep versus moderate neuromuscular block, whilst minimising variance in other anaesthetic techniques and drugs used. the outcome measured will be the post-operative quality of recovery over multiple time periods using the Postoperative Quality of Recovery Scale (PostopQRS). 350 patients will be enrolled over 4 centres.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
Objectives
- To identify whether the rate/quality of recovery is affected by deep neuromuscular block (DNB) and reversal with sugammadex versus light/moderate neuromuscular block reversed with neostigmine and couple with desflurane or sevoflurane in patients undergoing operative gynecological or abdominal laparoscopic surgery of at least 1-hour duration.
Hypothesis
- The technique of deep neuromuscular block and reversal with sugammadex will result in improved quality of recovery, including cognition, compared to the current standard of care technique using light/moderate neuromuscular block reversed with neostigmine in patients undergoing operative gynecological or abdominal laparoscopic surgery of at least 1-hour duration.
Background:
Importance and assessment of quality of recovery
Recovery following general anesthesia is a complex issue confounded by the type of surgery, inflammation, different anesthetic drugs and techniques, patient co-morbidities, and differing patient and clinician perceptions of what constitutes good recovery.
Recovery is not a single entity but rather covers many aspects or domains such as physiological recovery, pain and nausea, emotion and mood, return to normal life or work activities, and cognitive function. It is an entity that is difficult to quantify, which then makes it difficult to study in a systematic manner. For anesthesiologists, poor recovery is often relayed by the surgeon days or weeks after the event, and it is usually categorized as an adverse outcome.
Research tools such as the Aldrete or the QoR scales, focus on early physiological recovery, or the immediate perioperative period. These recovery scores are not sensitive enough to measure the rate of recovery (change over time), and have not been designed for repeated measures. They are also inadequate to identify poor cognitive recovery.
In 2007, an international group of anesthesiologists and neuropsychologists formed an advisory board to create a new quality of recovery scale. The aim was to produce a tool that was simple to perform, but sensitive enough to detect change in multiple domains of recovery over time. The initial validation experiment included over 700 patients, and this work has been published in Anesthesiology. It is called the Postoperative Quality Recovery Scale (PostopQRS). Six domains of recovery are identified: physiological, nociceptive (pain and nausea) emotive (anxiety and depression), functional recovery (return of activities of daily living), cognitive recovery, and an overall patient perspective domain including satisfaction. The scale is completed prior to surgery to provide baseline values, and then repeated at user-defined intervals. From some of the subsequent discriminant validation studies, time points have included early and late measures such as 15 minutes, 40 minutes, 1 and 3 days, and 3 months after the completion of anesthesia (typically defined as after the last surgical stimulation). Recovery is broadly defined as return to baseline values or better, except for the cognitive domain where a tolerance factor is included to allow for normal performance variability, such that patients are allowed to perform a little worse than baseline as still be scored as recovered. Because repeated tests tend to have a learning effect, the cognitive domain uses parallel forms, and only a small learning has been shown.
One of the most important benefits of the PostopQRS scale is that it enables recovery to be quantified and measured. This makes it possible to compare different interventions with the express purpose of developing clinical interventions to improve quality of recovery. The PostopQRS offers a tool to provide the recovery process to be examined. There are no other tools in existence that provide a comprehensive, sensitive assessment of the multiple aspects or domains of recovery, and is yet relatively simple to perform. Validation studies have been performed and show good discriminative ability (5-8). Ease of use is facilitated by using a web based data entry system and the ability to use the telephone to conduct surveys after discharge form hospital. Telephone survey has been shown to be equivalent to face to face interviews using the PostopQRS. Further, the PostopQRS allows users to drill down to identify which recovery domain is affected for individuals in real time as well as for group audit.
Quality of recovery after operative laparoscopy
The majority of the literature compares different operative techniques with outcome measures aimed at specific complications or length of stay. Few studies include quality of recovery or quality of life measures as secondary endpoints. However, for potential benefits relating to the use of sugammadex, there are a few studies primarily centered around deep neuromuscular block (DNB) facilitating low intraabdominal inflation pressures. Most outcomes relate to operative conditions with little data on patient centered outcomes especially after discharge. The inclusion of sugammadex is to permit the use of DNB, and most comparative groups (of moderate block) are reversed with neostigmine.
It has been shown that more patients can be operated on with low intraabdominal pressure with DNB, and that operative conditions are rated as better in more patients with DNB, though it is not absolute and there are frequent crossovers. That is, there are patients with moderate block and low pressure, and equally patients with DNB requiring high inflation pressures. The very few data on patient centered outcomes show reduced pain and nausea after DNB, but lack of evidence of benefit for other recovery outcomes. This paucity of data has been stressed by review articles and editorials that DNB is associated with a modest effect on improving operating conditions but very little data to identify recovery benefits.
Sugammadex is an effective drug to reduce deep neuromuscular blockade
There is no clinical question that sugammadex is highly effective in reversing neuromuscular blockade with rocuronium or vecuronium. This has been the subject of a Cochrane review which included 18 randomized trials, showing that sugammadex can reverse blockade with rocuronium or vecuronium independent on the depth of block, and superiority to neostigmine. This aspect of sugammadex does not require further study. This translates to a low incidence of residual blockade in the PACU compared to neostigmine reversal. The "safety" benefit to using sugammadex has been proven, but this does not necessarily translate into better outcomes. Sugammadex, however, is an enabling drug to facilitate deep neuromuscular blockade, allowing the anesthesiologist to continue that block until the end of surgery and reliably reverse the block. This is just not possible with neostigmine reversal, as one must wait until a train of four count of at least 2 twitches (or TOF ratio > 0.7) to safely reverse the block with neostigmine.
Sugammadex is not a single intervention
The role of sugammadex as a single intervention can only be applied when reversing neuromuscular block, when the block is moderate and a TOF 0.7 is achieved, with the outcome restricted to reversal of blockade.
When sugammadex is used as a tool to facilitate deep muscular block, the intervention is principally the DNB rather than sugammadex. In any randomized trial comparing sugammadex with neostigmine for reversal of DNB, the extra time that anesthesia is continued in the neostigmine group will be a confounder on post-operative outcomes. In a study comparing sugammadex vs. neostigmine to reverse DNB, the anesthetic time in the neostigmine group was almost double that of the sugammadex group (47 vs 95 min). This markedly increased anesthetic duration was due to the time taken for the TOF ratio to exceed 0.9 and facilitate safe extubation. It is therefore not possible to examine the issue of deep neuromuscular block and unbundle sugammadex from the anesthetic technique required.
Outcomes and confounders when assessing post-operative quality of recovery There are a few data assessing the impact of anesthetic drugs rather than surgical techniques or different operations on the post-operative quality recovery. It is very likely that different anesthetic drugs may independently contribute to changes in post-operative quality of recovery, over and above the use of deep neuromuscular block for laparoscopic surgery.
The two most commonly used anesthetic drugs are propofol and sevoflurane. Both are relatively short acting drugs, but have a wide variation of offset, particularly with more prolonged anesthesia, and patient factors such as morbid obesity. Desflurane is a volatile agent which is very short acting, and more importantly has highly predictable offset, which is independent of patient factors such as obesity or of operation duration. In patients receiving moderate neuromuscular block and reversal with neostigmine, the use of desflurane lead to earlier response to command and return of airway reflexed compared to sevoflurane.
The investigators research group is currently conducting research into different anesthetic techniques. Previously, the investigators studied effect of desflurane vs. propofol in patients undergoing cardiac surgery, and showed less cognitive dysfunction one week after surgery but not at three months after surgery with desflurane. The investigators have recently concluded but not published a pilot study investigating propofol sedation vs. desflurane general anesthesia to supplement spinal anesthesia for total hip replacement. The participant numbers are too small for meaningful statistical analysis, but there is a trend towards improved recovery and better cognitive recovery in the desflurane group (absolute difference 15% and OR 2.3). What is interesting, though, is that the early differences were negligible, and the trend occurred at 1 month and 3 months after surgery.
In this study, the investigators wish to primarily investigate the effect of the role of DNB, and to reduce the potential for confounding from different anesthetic techniques, we will standardize the anesthetic to use the shortest acting anesthetic bundle, and use desflurane coupled with short acting opiates and multimodal analgesia in patients undergoing operative gynecological or abdominal laparoscopic surgery of at least 1-hour duration.
Clinical significance
Quality of recovery is an emerging field within anesthesia of great importance. Although large outcome studies are very important in anesthesia, there is a changing focus from "mortality and morbidity studies", to quality of recovery. The reason is that the frequency of mortality is now very low with the result that few interventions will further reduce mortality and in any event very large numbers will be required to demonstrate any improvements in surgery and anesthesia with mortality as an outcome. However early data on the PostopQRS as well as clinical reports indicate that the quality of recovery is often poor in many patients, and yet these are not identified by the treating anesthesiologist. There are implications for the individual patient, for the practice of anesthesia, and for the community (such as safe return to work or to driving).
If providing deep neuromuscular block does lead to improved quality outcomes, then it is essential to use sugammadex to reverse the block. There may be benefits (such as cognitive recovery) that may be worsened by drugs such as neostigmine and avoidance of neostigmine may be a mechanism of improving recovery. The coupling of drugs with similar offset times may further lead to improved quality of recovery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: ModNMB Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more Neostigmine |
Drug: Neostigmine
Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
|
| Active Comparator: DeepNB Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex |
Drug: Sugammadex
Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
|
Outcome Measures
Primary Outcome Measures
- Percentage of Patients Recovered Cognitively at 1 Week [1 week]
The primary outcome will be the cognitive domain at 1 week after surgery, when it is expected that most of the acute inflammation will have resolved, and analgesia requirements minimal.
Secondary Outcome Measures
- Percentage of Patients Recovered in All Domains of the Postoperative Quality of Recovery Scale at 3 Months After the Operation [3 months]
Recovery for all domains and within domains of the PostopQRS scale at the other time points of measurement (15 minutes, 40 minutes 1 day, 3 days, 1 and 2 weeks, and 3 months following cessation of anesthesia). The domains of recovery are physiological, nociceptive, emotive activities of daily living, cognitive and overall patient perspective.
- Number of Participants With Full Reversal of Neuromuscular Blockade Prior to Extubation [6 hours]
Compliance with protocol to ensure deep block or light/moderate block, using the train of four ratio and post tetanic count
- Duration of Anesthesia From Induction to Cessation of the Anesthetic [Up to 6 hours]
Duration of Anesthesia from induction to cessation of the anesthetic up to 6 hours
- Number of Participants Categorized by Level of Surgical Satisfaction [2 hours]
Overall surgical satisfaction using a 1-5 Likert scale (1 = very unacceptable, 2 = unacceptable, 3 = acceptable, 4 = good, 5 = excellent).
- Duration of Hospital Length of Stay [3 days]
Duration of hospital length of stay following their procedure until hospital discharge
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult participants
-
operative gynecological or abdominal surgery
-
receiving general anesthesia
-
Operation expected to exceed1 hour duration
-
Participants must speak sufficient English to answer the survey questions
Exclusion Criteria:
-
Participants undergoing diagnostic laparoscopy only
-
Participants <18 years of age
-
Current pregnancy
-
Known allergy to rocuronium, neostigmine or sugammadex, or desflurane
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Northpark Private Hospital | Bundoora | Victoria | Australia | 3083 |
| 2 | Melbourne Health | Parkville | Victoria | Australia | 3050 |
| 3 | The Royal Womens Hospital | Parkville | Victoria | Australia | 3050 |
| 4 | Victorian Comprehensive Cancer Centre | Parkville | Victoria | Australia | 3050 |
Sponsors and Collaborators
- University of Melbourne
- Melbourne Health
- Peter MacCallum Cancer Centre, Australia
- Royal Hospital For Women
- Northpark Private Hospital
Investigators
- Principal Investigator: Colin Royse, MD, University of Melbourne
Study Documents (Full-Text)
More Information
Publications
None provided.- 2016.343
Study Results
Participant Flow
| Recruitment Details | In the period from June 2017 until November 2018, 350 patients were enrolled across 4 hospital sites (100 patients from the Royal Melbourne Hospital, 98 from the Peter MacCallum Cancer Centre, 88 from the Royal Women's Hospital and 64 from North Park Private Hospital). |
|---|---|
| Pre-assignment Detail | No participants were excluded from the study prior to surgical procedure |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Period Title: Overall Study | ||
| STARTED | 175 | 175 |
| COMPLETED | 144 | 140 |
| NOT COMPLETED | 31 | 35 |
Baseline Characteristics
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex | Total |
|---|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. | Total of all reporting groups |
| Overall Participants | 175 | 175 | 350 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
54.6
(16.3)
|
54.4
(15.5)
|
54.5
(15.9)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
102
58.3%
|
79
45.1%
|
181
51.7%
|
| Male |
73
41.7%
|
96
54.9%
|
169
48.3%
|
| Race and Ethnicity Not Collected (Count of Participants) | |||
| Count of Participants [Participants] |
0
0%
|
||
| Region of Enrollment (participants) [Number] | |||
| Australia |
175
100%
|
175
100%
|
350
100%
|
| ASA Status (Count of Participants) | |||
| ASA I |
24
13.7%
|
30
17.1%
|
54
15.4%
|
| ASA II |
99
56.6%
|
104
59.4%
|
203
58%
|
| ASA III |
45
25.7%
|
38
21.7%
|
83
23.7%
|
| BMI (kg/m^2) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [kg/m^2] |
29.5
(6.0)
|
28.8
(6.1)
|
29.2
(6.0)
|
| Education (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
13.5
(4.0)
|
13.3
(3.4)
|
13.4
(3.5)
|
| Alcohol consumption (units/week) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [units/week] |
4.8
(8.1)
|
3.9
(6.3)
|
4.3
(7.2)
|
| Previous smoker (Count of Participants) | |||
| Count of Participants [Participants] |
85
48.6%
|
86
49.1%
|
171
48.9%
|
| Current Smoker (Count of Participants) | |||
| Count of Participants [Participants] |
24
13.7%
|
15
8.6%
|
39
11.1%
|
| Employment (Count of Participants) | |||
| Count of Participants [Participants] |
93
53.1%
|
114
65.1%
|
207
59.1%
|
| Surgical access (Count of Participants) | |||
| Laparoscopic surgery |
125
71.4%
|
131
74.9%
|
256
73.1%
|
| Robotic-assisted |
50
28.6%
|
44
25.1%
|
94
26.9%
|
| Out-patient (Count of Participants) | |||
| Count of Participants [Participants] |
12
6.9%
|
13
7.4%
|
25
7.1%
|
| Anaesthetic technique (Count of Participants) | |||
| General anaesthesia |
164
93.7%
|
164
93.7%
|
328
93.7%
|
| Spinal anaesthesia |
11
6.3%
|
9
5.1%
|
20
5.7%
|
| Regional block |
0
0%
|
2
1.1%
|
2
0.6%
|
Outcome Measures
| Title | Percentage of Patients Recovered Cognitively at 1 Week |
|---|---|
| Description | The primary outcome will be the cognitive domain at 1 week after surgery, when it is expected that most of the acute inflammation will have resolved, and analgesia requirements minimal. |
| Time Frame | 1 week |
Outcome Measure Data
| Analysis Population Description |
|---|
| There were 31 participants who did not complete the cognitive assessment at 1 week in the moderate neuromuscular blockade group, whereas there were 35 participants who did not complete the cognitive assessment at 1 week in the deep neuromuscular blockade group |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Measure Participants | 144 | 140 |
| Number [percentage of patients recovered] |
91.8
|
92.9
|
| Title | Percentage of Patients Recovered in All Domains of the Postoperative Quality of Recovery Scale at 3 Months After the Operation |
|---|---|
| Description | Recovery for all domains and within domains of the PostopQRS scale at the other time points of measurement (15 minutes, 40 minutes 1 day, 3 days, 1 and 2 weeks, and 3 months following cessation of anesthesia). The domains of recovery are physiological, nociceptive, emotive activities of daily living, cognitive and overall patient perspective. |
| Time Frame | 3 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| Recovery in all domains of the Postoperative Quality of Recovery Scale at 3 months after the operation |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Measure Participants | 175 | 175 |
| Number [percentage of patients recovered] |
75.7
|
73
|
| Title | Number of Participants With Full Reversal of Neuromuscular Blockade Prior to Extubation |
|---|---|
| Description | Compliance with protocol to ensure deep block or light/moderate block, using the train of four ratio and post tetanic count |
| Time Frame | 6 hours |
Outcome Measure Data
| Analysis Population Description |
|---|
| Full reversal prior to extubation (4 twitches and TOF ratio >0.9) |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Measure Participants | 175 | 175 |
| Number [participants] |
158
90.3%
|
161
92%
|
| Title | Duration of Anesthesia From Induction to Cessation of the Anesthetic |
|---|---|
| Description | Duration of Anesthesia from induction to cessation of the anesthetic up to 6 hours |
| Time Frame | Up to 6 hours |
Outcome Measure Data
| Analysis Population Description |
|---|
| Duration of Anesthesia from induction to cessation of the anesthetic |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Measure Participants | 175 | 175 |
| Mean (Standard Deviation) [minutes] |
165.4
(88.8)
|
164
(96)
|
| Title | Number of Participants Categorized by Level of Surgical Satisfaction |
|---|---|
| Description | Overall surgical satisfaction using a 1-5 Likert scale (1 = very unacceptable, 2 = unacceptable, 3 = acceptable, 4 = good, 5 = excellent). |
| Time Frame | 2 hours |
Outcome Measure Data
| Analysis Population Description |
|---|
| Surgical operating conditions |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. |
| Measure Participants | 166 | 165 |
| Excellent |
104
59.4%
|
94
53.7%
|
| Good |
38
21.7%
|
48
27.4%
|
| Acceptable |
20
11.4%
|
16
9.1%
|
| Unacceptable |
3
1.7%
|
1
0.6%
|
| Very Unacceptable |
1
0.6%
|
1
0.6%
|
| Title | Duration of Hospital Length of Stay |
|---|---|
| Description | Duration of hospital length of stay following their procedure until hospital discharge |
| Time Frame | 3 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Duration of hospital length of stay following their procedure until hospital discharge |
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex |
|---|---|---|
| Arm/Group Description | Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more Neostigmine Neostigmine: Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present. | Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex Sugammadex: Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. |
| Measure Participants | 175 | 175 |
| Mean (Standard Deviation) [days] |
2.6
(3.5)
|
1.8
(1.9)
|
Adverse Events
| Time Frame | 3 months | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex | ||
| Arm/Group Description | The initial dosage of a moderate block was 0.6mg/kg of rocuronium, with repeat dosage of 0.15mg/kg given if the TOF > 2. Once the TOF had 2 twitches, 50mcg/kg Neostigmine coupled with 20mcg/kg of atropine or 5mcg/kg of glycopyrrolate was administered for the reversal of a moderate block with a maximum dosage of 5.0mg of neostigmine. Extubation occurred when the TOF = 4 with no visible fade. | The initial dosage of deep block was 1.2mg/kg with repeat dosages of 0.15mg/kg until PTC ≤ 2. Sugammadex dosage was adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. The dosage was 4mg/kg when TOF=0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1. Extubation occurred when the TOF=4 with no visible fade. | ||
All Cause Mortality |
||||
| Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/175 (0%) | 0/175 (0%) | ||
Serious Adverse Events |
||||
| Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/175 (0%) | 0/175 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Moderate Neuromuscular Blockade Reversed With Neostigmine | Deep Neuromuscular Blockade Reversed With Sugammadex | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/175 (0%) | 0/175 (0%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Prof Colin Royse |
|---|---|
| Organization | The University of Melbourne |
| Phone | +61408467548 |
| Colin.Royse@unimelb.edu.au |
- 2016.343